Chicago / Edinburgh
IPOX® Schuster LLC
Home / IPO Calendar
United States · Nasdaq

Kardigan

Kardigan develops medicines for cardiovascular conditions and provides a data and analytics platform supporting clinical trials.

Kardigan (Ticker: KARD US) develops medicines for cardiovascular conditions, including candidates for heart muscle disease, narrowed heart valves and severe high blood pressure after hospitalization. Prolaio is a data and analytics platform that uses wearable sensors and artificial intelligence to support clinical trials and digital measures of patient outcomes. Founded in 2023, the company had 241 employees. For the 12 months ended March 31, 2026, it reported no product revenue and a net loss of approximately $230.00 million.

The scheduled listing date on Nasdaq was June 18, 2026. The proposed offering comprises 23,330,000 shares at an indicative price range of $14.00–16.00 per share. At the indicative range midpoint, the base offering would represent $349.95 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $1.30 billion.

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are joint bookrunners.

Prepared with IPOX® AI assistance. Information may contain errors.

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends

Reuters · June 20, 2026

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends

IPOX® Associate Muehlbauer was quoted by Reuters on Kardigan’s Nasdaq debut, after the heart drug developer raised $400 million in an upsized IPO. He noted that biotech IPO activity has improved but remains selective, favoring companies with late-stage assets, clear commercialization paths, visible catalysts, or strong backers. In broader commentary shared with Reuters, Muehlbauer said Kardigan’s going-concern warning was not a deal breaker and reflected why the company raised capital, while follow-on offerings remain a possible overhang for investors.

Read article : Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s IPO and Biotech Market Recovery

Reuters · June 12, 2026

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s IPO and Biotech Market Recovery

IPOX® Associate Lukas Muehlbauer was cited by Reuters on Kardigan’s planned U.S. IPO, which targets a valuation of up to $1.4 billion and aims to raise as much as $373.3 million. Muehlbauer noted a “clear uptick in biotech IPOs” and said healthcare IPO activity has already surpassed last year’s deal flow, signaling an open window for the sector. He also cautioned that investors remain selective, favoring companies with clinical progress and clearer paths to FDA approval.

Read article : Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s IPO and Biotech Market Recovery

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters